Scientia Advisors in the News

---

Publications

---

Press Releases

---

Events

---

Luminary Insights

---

Media Contact

---

Scientia Advisors in the News

The Boston Globe quotes Harry Glorikian in "Genzyme's in play, and it's all about price"

Robert Weisman
August 3rd, 2010

In this article by Robert Weisman of the Boston Globe, Scientia Advisors' Managing Partner Harry Glorikian explains the current slate of biotech buyouts in financial terms. "There are patent cliffs coming where their drugs come off patents and revenue will drop precipitously. So they need to diversify and feed the revenue beast."

For more information see The Boston Globe